Comparison of sedation strategies for critically ill patients

Hutton, Brian; Burry, Lisa D.; Kanji, Salmaan; Mehta, Sangeeta; Guenette, Melanie; Martin, Claudio M.; Fergusson, Dean A.; Adhikari, Neill K.; Egerod, Ingrid Eugenie; Williamson, David; Straus, Sharon; Moher, David; Ely, E. Wesley; Rose, Louise

Published in:
Systematic Reviews

DOI:
10.1186/s13643-016-0338-x

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Hutton, B., Burry, L. D., Kanji, S., Mehta, S., Guenette, M., Martin, C. M., ... Rose, L. (2016). Comparison of sedation strategies for critically ill patients: A protocol for a systematic review incorporating network meta-analyses. DOI: 10.1186/s13643-016-0338-x
Comparison of sedation strategies for critically ill patients: a protocol for a systematic review incorporating network meta-analyses

Brian Hutton1,2*, Lisa D. Burry3,4†, Salmaan Kanji1,5, Sangeeta Mehta6,7, Melanie Guenette4, Claudio M. Martin8,9, Dean A. Ferguson1,10,11, Neill K. Adhikari6,12,13, Ingrid Egerod14, David Williamson15,16, Sharon Straus17, David Moher1,2,11, E. Wesley Ely18 and Louise Rose12,13,19,20,21

Abstract

**Background:** Sedatives and analgesics are administered to provide sedation and manage agitation and pain in most critically ill mechanically ventilated patients. Various sedation administration strategies including protocolized sedation and daily sedation interruption are used to mitigate drug pharmacokinetic limitations and minimize oversedation, thereby shortening the duration of mechanical ventilation. At present, it is unclear which strategy is most effective, as few have been directly compared. Our review will use network meta-analysis (NMA) to compare and rank sedation strategies to determine their efficacy and safety for mechanically ventilated patients.

**Methods:** We will search the following from 1980 to March 2016: Ovid MEDLINE, CINAHL, Embase, PsycINFO, and Web of Science. We will also search the Cochrane Library, gray literature, and the International Clinical Trials Registry Platform. We will use a validated randomized control trial search filter to identify studies evaluating any strategy to optimize sedation in mechanically ventilated adult patients. Authors will independently extract data from eligible studies in duplicate and complete the Cochrane Risk of Bias tool. Our outcomes of interest include duration of mechanical ventilation, time to first extubation, ICU and hospital length of stay, re-intubation, tracheostomy, mortality, total sedative and opioid exposure, health-related quality of life, and adverse events. To inform our NMA, we will first conduct conventional pair-wise meta-analyses using random-effects models. Where appropriate, we will perform Bayesian NMA using WinBUGS software.

**Discussion:** There are multiple strategies to optimize sedation for mechanically ventilated patients. Current ICU guidelines recommend protocolized sedation or daily sedation interruption. Our systematic review incorporating NMA will provide a unified analysis of all sedation strategies to determine the relative efficacy and safety of interventions that may not have been compared directly. We will provide knowledge users, decision makers, and professional societies with ranking of multiple sedation strategies to inform future sedation guidelines.

**Systematic review registration:** PROSPERO CRD42016037480

**Keywords:** Sedation protocol, Daily sedation interruption, Mechanical ventilation, Intensive care, Systematic review, Network meta-analysis

* Correspondence: bhutton@ohri.ca
† Equal contributors
1 Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Rd, Ottawa, ON K1H8L6, Canada
2 School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, ON, Canada
Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Sedatives and analgesics are administered in 60–90% of critically ill patients to manage agitation, reduce pain, and facilitate mechanical ventilation [1–4]. Despite their widespread use, accumulating data indicate these drugs may prolong mechanical ventilation [1, 5–14] and increase delirium [15, 16], long-term cognitive impairment [8, 15], and mortality [10–13]. In this analysis, we will provide a ranking of multiple strategies used to optimize sedation in mechanically ventilated patients to inform future sedation guidelines.

The provision of optimal sedation in critically ill patients is challenging for a number of reasons, including fluctuating illness acuity, the presence of delirium and other disease-associated brain dysfunction (e.g., encephalopathy), pre-morbid psychiatric disorders, and risk of drug or alcohol withdrawal. In addition, multi-organ dysfunction and polypharmacy can render drug pharmacokinetics and dynamics unpredictable, increasing the risk for adverse events and drug interactions. Given these complexities, an ideal sedative or analgesic for critically ill patients would include minimal drug accumulation, ease of titration, tolerable adverse effects, and a clean drug interaction profile (i.e., avoidance of cytochrome P450 metabolism), all at a reasonable cost. At this time however, no sedative or analgesic drug satisfies all these criteria. Despite this, drug administration strategies exist that attempt to mitigate the pharmacokinetic limitations of available drugs; the most common approaches include daily sedation interruption, nurse-directed protocolized sedation, analgesia-based sedation or no sedation, and intermittent dosing versus continuous infusions.

Daily sedation interruption is defined as a short-term suspension, hold, discontinuation, or cessation of intravenous sedative or in some cases, analgesic medication [13]. This approach is used to allow elimination or prevent accumulation of drug, promote patient wakefulness to gauge tolerance for complete cessation of sedation and/or liberation from invasive mechanical ventilation, and where necessary, identify the smallest effective dose of drug to be used. Protocolized sedation involves the titration of sedative and analgesic drugs by intensive care unit (ICU) nurses using a standardized algorithm and sedation assessment scale, most commonly to achieve patient-targeted light sedation [7]. Analgesia-base sedation aims to achieve adequate analgesia while avoiding the use of sedative drugs [14]. Prioritization of analgesia is important due to the high prevalence of pain and discomfort in the critically ill, which can manifest as agitation. Lastly, continuous intravenous drug infusions [12] permit more stable plasma concentrations, which may facilitate sedation control compared to intermittent dosing; however, continuous infusions can lead to drug accumulation if not titrated closely.

The most recent Society of Critical Care Medicine (SCCM) guidelines [17] recommend protocolized sedation or daily sedation interruption to achieve light sedation in mechanically ventilated ICU patients. These guidelines, however, are based on traditional pair-wise meta-analytic techniques, which only compare two interventions at a time (e.g., daily interruption vs. usual care). Given the growing number of clinical trials and sedation strategies in use, we propose a synthesis of existing data using network meta-analysis (NMA), a novel statistical approach enabling both direct and indirect comparisons in a multi-treatment analytical framework [18–20]. This powerful statistical tool will allow the determination of the relative efficacy and safety of interventions that may or may not have been previously compared head-to-head in randomized controlled trials.

Methods/design

This review protocol was prepared using the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocol (PRISMA-P) guidelines [21]. We completed the PRISMA-P checklist (Additional file 1). The protocol for this review has been registered using the PROSPERO International Prospective Register of Systematic Reviews (CRD42016037480).

Data sources and search strategy

Team leaders LB, BH, and LR created a preliminary search strategy (Additional file 2) with an experienced senior information specialist. Prior to execution of the search, a second senior information specialist reviewed the strategy using the Peer Review for Electronic Search Strategies (PRESS) template [22, 23]. The following electronic databases will be searched from 1980 to March 2016: Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, CINAHL, Embase Classic +Embase, PsycINFO, and Web of Science. We will not apply a language restriction. We will use a validated randomized controlled trial filter and perform a separate search for published systematic reviews and protocols in the Cochrane Library and PROSPERO. We will form a grey literature search using sources listed in the Canadian Agency for Drugs and Technologies in Health’s (CADTH) Grey Matters [24]. We will search for unpublished and ongoing trials on the International Clinical Trials Registry Platform (http://apps.who.int/trialsearch). We will search the reference lists of relevant articles and systematic reviews for studies not identified through electronic searches. To avoid duplicate study selection, we will compare author names and affiliations, as well as study characteristics, and where uncertainty remains, we will contact corresponding authors for clarification.

Study eligibility criteria

We will include randomized controlled trials, including those using open-label and quasi-randomized (i.e., quasi-random method of allocation such as alternation)
designs. We will include studies that evaluate any sedation strategy in mechanically ventilated adults.

**Population**
Our population of interest is mechanically ventilated, critically ill adults aged 16 years and older and treated in any type of ICU (e.g., burn, cardiac, medical, surgical, trauma, or mixed) or high acuity unit (e.g., high dependency, step-up, step-down units).

**Intervention**
We will include trials that evaluate any sedation administration strategy in mechanically ventilated adults. Expected interventions include (1) daily sedation interruption (i.e., daily cessation of sedative, and on occasion analgesic drugs), (2) protocolized sedation (i.e., drug titration by ICU nurses using standardized algorithm and assessment tools to targeted patient sedation level), (3) analgesia-based sedation (i.e., opioid managed analgesia, with minimal or no sedative use), (4) intermittent dosing (i.e., bolus dosing, common in long acting drugs), (5) continuous dosing (i.e., uninterrupted intravenous dosing, common in short acting drugs), and (6) volatile gases (i.e., volatile anaesthetic agents for sedation). No restrictions will be placed on study selection based on drug class, dose, route or duration of administration. Each intervention will have an individual node in the analytical network (Fig. 1) and additional interventions not specified above will be considered should their studies meet inclusion criteria.

**Comparators**
NMA, an extension of the traditional meta-analytic technique, enables comparisons of multiple interventions based on both direct and indirect evidence [19, 20, 25]. This novel statistical approach will permit the consideration of any trial evaluating any sedation strategies, whether compared to each other or to usual care. Descriptions of usual care will be extracted verbatim from included studies to ensure similarities and differences are appropriately reflected in the network structure used to perform NMA.

**Outcomes**
Our primary outcome is the duration of invasive mechanical ventilation, defined as the time (in days) from intubation to successful extubation, without requirement of re-intubation (or ventilator support in the case of tracheostomy) for a minimum of 24 h. The duration of mechanical ventilation is the primary outcome for most ICU sedation trials.

Secondary outcomes include the following: hospital and ICU length of stay, time to first extubation, tracheostomy, reintubation, mortality, total sedative and opioid exposure (using midazolam and fentanyl equivalents, respectively), use of physical restraints, health-related
quality of life, and adverse events (e.g., accidental removal of endotracheal tube or catheter, incidence of delirium, and cardiac events (e.g., ST elevation myocardial infarction (STEMI) or non-STEMI)). As mortality may be defined at various time points, we will extract all reported mortality outcomes and create subgroups where needed for descriptive and analytical purposes.

**Screening and data extraction**

Two authors (LB, MG) will independently screen search results against eligibility criteria to identify relevant trials. Prior to screening, we will perform a calibration exercise by piloting the screening tool on a sample of ten studies to ensure consistency in the application of eligibility criteria. References will be organized using the reference management software package EndNote (X7 edition, Thomson Reuters, available at http://endnote.com/). We will examine the full text of any title or abstract selected by either author to determine study inclusion eligibility; in the event of a disagreement, an independent arbiter (LR) will be consulted. Reasons for study exclusion will be documented in the notes field of EndNote. We will report the search strategy and study selection process using a PRISMA flow diagram [26].

We will divide data extraction among pairs of authors (SK/SM, NA/MG, DW/IE). Each member of the author pair will independently extract data using a standardized electronic form that was developed by two authors (BH, MG) in Microsoft Excel version 14.6.2 (Microsoft Corporation, Seattle, WA, USA). The extraction form will be piloted on five studies to ensure its capture of all relevant data (MG, LB). We will extract data related to study design, setting, patient characteristics (e.g., age, gender, severity of illness score, reason for ICU admission), study interventions, co-interventions potentially affecting duration of mechanical ventilation (e.g., spontaneous breathing trials), and stated outcomes of interest.

In the event of missing or unclear data, we will contact study authors directly. Any discrepancies between data extractors will be resolved through discussion with an independent arbiter (LB).

**Risk of bias assessment**

Each data extractor will be responsible for assessing the risk of bias of their allocated studies, and a third author (LR) will confirm the final assessment, where necessary. We will use a domain-based evaluation for risk of bias assessment, as recommended by the Cochrane Collaboration [27]. The domains include the following: (1) random sequence generation (i.e., selection bias); (2) allocation concealment (i.e., selection bias); (3) blinding of participants and personnel (i.e., performance bias); (4) blinding of outcomes assessment (i.e., detection bias); (5) incomplete outcome data (i.e., attrition bias); (6) selective reporting; and (7) other bias (e.g., study source of funding). Lack of blinding will not be considered to confer a high risk of bias for objective endpoints such as mortality because the process of blinding is unlikely to influence results.

For each domain, we will assess the risk of bias as “low,” “high,” or “unclear.” Unclear risk will be assigned for a domain if insufficient detail is reported and cannot be obtained from study authors, or if what happened in the study is known, but its contribution to the risk of bias is unknown or unclear. After the assignment of risk of bias, studies will be categorized as follows:

1. Low risk: all domains are considered to be at “low” risk of bias;
2. High risk: one or more domains are considered to be at “high” risk of bias; and
3. Unclear risk: one or more domain(s) have “unclear” risk of bias (and no domain at high risk of bias).

**Approach to evidence synthesis**

In the NMA, each intervention will have its own node (Fig. 1). If we encounter combined interventions, the research team will be consulted to determine the best approach for analysis.

Members of the research team will inspect the characteristics of included studies to assess their clinical and methodological homogeneity. We will review the distribution of potential effect modifiers across studies to determine the validity of the assumptions of homogeneity and similarity; [28] these modifiers will likely relate to patient demographics (e.g., age, gender), eligibility criteria (e.g., concomitant medication use), and study design (e.g., blinding, duration of follow-up). For comparisons in the network where a minimum of two studies is available, we will also perform conventional pair-wise meta-analyses using a random-effects model, and derive estimates of between-study heterogeneity of treatment effects (with \( I^2 > 50 \% \) to be considered indicative of potential importance) [29]. These assessments will permit judgments about whether sufficient homogeneity exists within comparisons in the treatment network. If homogeneity is established, we will progress to performing the planned NMA.

We will perform NMA within a Bayesian framework, assuming a common heterogeneity parameter across all comparisons, and accounting for correlations in multi-arm studies. Analyses will be performed using WinBUGS software [30] (version 1.4.3, MRC Biostatistics Unit, Cambridge, UK) (http://www.mrc-bsu.cam.ac.uk/software/bugs/the-bugs-project-winbugs/) through well-established methods [31, 32]. Continuous and binary outcomes will be expressed in terms of mean differences and odds ratios,
respectively, with corresponding 95% confidence intervals [33–35]. Surface Under the Cumulative Ranking (SUCRA) curve estimates will also be provided [32].

Model adequacy of fit will be evaluated through comparison of the posterior deviance with the number of unconstrained data points (i.e., the total number of intervention arms across studies) [35], and adequacy of fit will be deemed present when these quantities are approximately equal. Both fixed- and random-effects consistency models will be run, and their fit will be examined via comparison of the Deviance Information Criterion (DIC), which penalizes model fit for complexity (note, lower values indicate better models) [36]. A difference of five points or more will be considered indicative of an important difference. We will fit inconsistency models and compare their DIC values with those of consistency models to detect inconsistency. If detected, variations in individual study characteristics will be explored as a potential cause, as will the need for additional statistical considerations such as meta-regression. Model convergence will be assessed using established methods including Gelman-Rubin diagnostics and inspection of Monte Carlo errors [35].

Subgroup and sensitivity analyses
We will explore subgroup and/or meta-regression analyses to address the impact of covariates on our findings in order to establish their robustness. If sufficient information is identified, we will perform subgroup analyses to determine if our findings are influenced by (1) drug class (e.g., short acting such as propofol vs. long-acting such as benzodiazepines) and (2) type of ICU population (e.g., medical vs. surgical). We will conduct sensitivity analyses excluding studies with high risk of bias and involving alternative geometries of the network. Examples of potential reformulations of the network include consideration of co-interventions known to shorten the duration of mechanical ventilation (e.g., weaning protocols).

Reporting of review findings
We will adhere to recommendations from the PRISMA-NMA extension statement on NMA for reporting our review findings [37]. We will include recommended graphical approaches such as forest plots, league tables, and rank-o-grams [32]. We will provide a summary of the geometries of the networks to provide insight for future sedation analgesia trials in mechanically ventilated, critically ill adults.

Dissemination of findings
We will use the knowledge-to-action framework, which emphasizes the successful implementation of research evidence into practice in two phases: (1) knowledge creation and (2) action. We will seek input from our knowledge users and affiliated organizations for knowledge translation opportunities. We will communicate the findings of this review via a one-page summary tailored to specific audiences (e.g., patients and family members, clinicians, researchers, policy makers), presentations delivered at local, national, and international forums, and publications in peer-reviewed journals. We will hold an end-of-project workshop where key stakeholders will further discuss findings, identify research gaps, and develop a knowledge translation plan to assist with adoption of our findings.

Discussion
Several sedation administration strategies have been developed to reduce oversedation and duration of mechanical ventilation in critically ill adults. Current critical care guidelines recommend the use of daily sedation interruption or protocolized sedation to achieve targeted light sedation [17]. Although these recommendations are based on a number of trials and systematic reviews, they have yielded mixed results [5, 7, 10, 13, 38–54]. Given the use of additional strategies that have not yet been compared directly (i.e., head-to-head) in clinical trials, we believe the NMA approach has the potential to identify the strategy that most effectively and safely avoids unnecessary days of mechanical ventilation. Despite the strengths of the NMA approach, our study may face certain limitations, such as the reconciliation of different endpoints (e.g., duration of follow-up and mortality measurements) and how to analyze more complex case mixes (e.g., mixed vs. specific ICU patient populations). This data synthesis will nonetheless allow comparisons of all available sedation strategies for mechanically ventilated, critically ill adults, thus providing clinicians, researchers, and professional societies alike with clarity regarding the relative efficacy and safety of available interventions.

Registration
This systematic review is registered with PROSPERO, an international prospective register of systematic reviews. http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016037480

Additional files

Additional file 1: Preferred Reporting Items for Systematic Review and Meta-Analyses Protocol (PRISMA-P). Description: PRISMA-P items and their respective line locations within the manuscript. (DOCX 135 kb)

Additional file 2: Preliminary search strategy. Description: Preliminary search strategy, including all queried databases, search parameters, and key words. (DOCX 118 kb)

Abbreviations
DIC: Deviance Information Criterion; ICU: Intensive care unit; NMA: Network meta-analysis; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis; SCCM: Society of Critical Care Medicine; STEMI: ST elevation myocardial infarction
Acknowledgements

We would like to acknowledge Becky Skidmore, Information Specialist (Systematic Reviews) for her assistance in the design and execution of the search strategy. We also thank Nicholas Ren, Pharmacy Student (University of Toronto), for his assistance in the protocol development.

Funding

This review has been funded by the Canadian Institutes of Health Research (CIHR) (Knowledge Synthesis competition Spring 2015). Dr. Brian Hutton is the recipient of a New Investigator Award from the Canadian Institutes of Health Research and the Drug Safety and Effectiveness Network. Dr. David Moher is funded by the University of Ottawa Research Chair. Dr. Louise Rose holds a CIHR New Investigator Award.

Authors’ contributions

BH designed the first draft of the review protocol, drafted the successful funding application to support the conduct of the review, and will manage and analyze the review data, perform statistical inferences, and participate in drafting the final manuscript. LB conceived of and is the guarantor of the review, designed the first draft of the review protocol, drafted the successful funding application to support the conduct of the review, and coordinate the review, manage and analyze the review data, and participate in drafting the final manuscript. MG designed the first draft of the review protocol, drafted the successful funding application to support the conduct of the review, and will coordinate the review, manage review data, and participate in drafting the final manuscript. LG conceived of the review, designed the first draft of the review protocol, drafted the successful funding application to support the conduct of the review, and will coordinate the review, manage review data, and participate in drafting the final manuscript. DM will manage and analyze the review data, perform statistical inferences, and participate in drafting the final manuscript. DG will manage and analyze the review data, perform statistical inferences, and participate in drafting the final manuscript. All authors participated in the refinement of the clinical questions and methodologies for the review protocol and have read and approved the submitted manuscript. They will all participate in the interpretation of the data and approve the final manuscript.

Competing interests

SM and LB conducted a randomized controlled trial [51] comparing protocolized sedation to protocolized sedation plus daily interruption that will meet inclusion criteria for this review. LB, LR, DF, and SM completed a Cochrane systematic review on daily sedation interruption compared to no daily sedation interruption (CDD009176). BH has previously received fees for methodological advice on NMA from Amgen Canada and Eisai Canada.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Author details

1Clinical Epidemiology Program, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Rd, Ottawa, ON K1H8L6, Canada. 2School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, ON, Canada. 3Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada. 4Department of Pharmacy, Mount Sinai Hospital, 600 University Avenue, Toronto, ON, M5G1X5, Canada. 5Department of Pharmacy, The Ottawa Hospital, Ottawa, ON, Canada. 6Department of Medicine, University of Ottawa, Ottawa, ON, Canada. 7School of Medicine, Interdepartmental Division of Critical Care, University of Toronto, Toronto, ON, Canada. 8Department of Medicine, Division of Critical Care, Mount Sinai Hospital, Toronto, ON, Canada. 9Department of Medicine, Division of Critical Care, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. 10Lawson Health Research Institute, London Health Sciences Centre, London, ON, Canada. 11Department of Medicine, University of Ottawa, Ottawa, ON, Canada. 12Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada. 13Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 14Sunnybrook Research Institute, Toronto, ON, Canada. 15University of Copenhagen, Rigshospitalet, Neurointensive Intensive Care, Copenhagen, Denmark. 16Faculté de Pharmacie, Université de Montréal, Montréal, QC, Canada. 17Département de Pharmacie, Hôpital du Sacré-Coeur, Montréal, QC, Canada. 18Knowledge Translation Program, Li Ka Shing Knowledge Institute, Saint Michael’s Hospital, Toronto, ON, Canada. 19Department of Medicine, Vanderbilt University Medical Center, Health Services Research Center, Nashville, TN, USA. 20Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada. 21Institute for Clinical Evaluative Sciences, Toronto, ON, Canada. 22Provincial Centre of Weaning Excellence, Toronto East General Hospital, Toronto, ON, Canada.

Received: 4 July 2016 Accepted: 13 September 2016

Published online: 20 September 2016

References

1. Anoligia A, Frutos-Vivar F, Hall J, Esteban A, Apoetaegua C, Soto L, et al. Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest. 2005;128(2):496–506.
2. Burry LD, Williamson DR, Pereault MM, Rose L, Cook DJ, Ferguson ND, et al. Analgesic, sedative, antipsychotic, and neuromuscular blocker use in Canadian intensive care units: a prospective, multicentre, observational study. Can J Anesth. 2014;61(7):619–30.
3. Mehta S, Burry L, Fischer S, Martinez-Motta J, Hallett D, Bowman D, et al. Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. Crit Care Med. 2006;34(2):374–80.
4. Mehta S, McCullagh J, Burry L. Current sedation practices: lessons learned from international surveys. Anesth Analg. 2011;129(4):607–24.
5. Arabi Y, Haddad S, Hawes R, Moore T, Pillay M, Naidu B, et al. Changing sedation practices in the intensive care unit—protocol implementation, multifaceted multidisciplinary approach and teamwork. Middle East J Anesthesiol. 2007;19(2):429–47.
6. Brattebo G, Hofoss D, Flaten H, Muri AK, Gjerde S, Plets AE. Effect of a scoring system and protocol for sedation on duration of patients’ need for ventilator support in a surgical intensive care unit. Qual Saf Health Care. 2004;13(2):203–5.
7. Brock AD, Ahrens TS, Schaff R, Prentice D, Sherman G, Shannon W, et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med. 1999;27(12):2609–15.
8. Burns SM, Earven S, Fisher C, Lewis R, Merrell P, Schubart JR, et al. Implementation of an institutional program to improve clinical and financial outcomes of mechanically ventilated patients: one-year outcomes and lessons learned. Crit Care Med. 2003;31(12):2752–63.
9. Canon SS, Kress JP, Rodgers JE, Vinayak A, Campbell-Bright S, Levitt J, et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med. 2006;34(5):1326–32.
10. Girard TD, Kress JP, Fuchs BD, Thomason JW, Schwerknd WD, Pun BT, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet. 2008;371(9607):126–34.
11. Jakob SM, Lubzky S, Frickel R, Rohlen HU, Kolarova A, Takaka J. Sedation and weaning from mechanical ventilation: effects of process optimization outside a clinical trial. J Crit Care. 2007;22(3):219–28.
12. Kollef MH, Levy NT, Ahrens TS, Schaff R, Prentice D, Sherman G. The use of continuous iv. sedation is associated with prolongation of mechanical ventilation. Chest. 1998;114(2):541–8.
13. Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342(20):1471–7.
14. Stram T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. Lancet. 2010;375(9713):475–80.
15. Kress JP, Gehlbach B, Lacy M, Pliksin N, Pohlman AS, Hall JB. The long-term psychological effects of daily sedative interruption on critically ill patients. Am J Respir Crit Care Med. 2003;168(12):1457–61.
16. Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, et al. Effect of sedation with dexmedetomidine versus lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644–53.
17. Barr J, Fraser GL, Puntikko K, Ely EW, Gelinas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):253–306.
18. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130–7.

19. Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ. 2009;181(8):468–93.

20. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105–24.

21. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.

22. McGowan J, Sampson M, Salzwedel DM, Cogo E, Forrester V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40–6.

23. Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol. 2009;62(9):944–52.

24. Tools NCCfMa. Searching grey literature: grey matters. 2012. Available from: http://www.nccfma/resources/search/130.

25. CateLA-Zep F, Tobies A, Cameron C, Moher D, Hutton B. Network meta-analysis for comparing treatment effects of multiple interventions: a tutorial. Rumatol Int. 2014;34(11):1149–96.

26. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7), e1000097.

27. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration. 2011. Available from: http://handbook.cochrane.org.

28. Donegan S, Williamson P, D’Alessandro U, Tudur Smith C. Assessing key assumptions of network meta-analysis: a review of methods. Res Synth Methods. 2013;4(4):291–323.

29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

30. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc. 2006;101(474):447–59.

31. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(12):1563–71.

32. Dias S, Sutton AJ, Welton NJ, Ades AE. Evidence synthesis for decision making 3: heterogeneity—subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making. 2013;33(5):618–40.

33. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials. 2011. Available from: http://www.nicedsu.org.uk.

34. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011. Available from: http://www.nicedsu.org.uk.

35. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B (Statistical Methodology). 2002;64(4):583–639.

36. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(1):777–84.

37. Adam C, Rosser D, Manji M. Impact of introducing a sedation management protocol-directed sedation versus non-protocol-directed sedation to reduce duration of mechanical ventilation in mechanically ventilated intensive care patients. Cochrane Database Syst Rev. 2015:1.

38. Aitken LM, Bucknall TK, Augustes R, Ho KM, Burmeister E, Keogh SJ. A randomized trial of protocol-directed sedation management for mechanical ventilation in an Australian intensive care unit. Crit Care Med. 2008;36(5):1444–50.

39. Aitken LM, Bucknall TK, Manias E, Presnell JJ. A randomized trial of protocol-directed sedation management for mechanical ventilation in an Australian intensive care unit. Crit Care Med. 2005;33(1):120–7.

40. Bunn L, Rose L, McCullagh U, Ferguson DA, Ferguson ND, Mehta S. Daily sedation interruption versus no daily sedation interruption for critically ill adult patients requiring invasive mechanical ventilation. Cochrane Database Syst Rev. 2014;7:CD009176.

42. de Jonghe B, Bastuji-Garin S, Fangio P, Lacherade JC, Jabot J, Appere-DeVecchi C, et al. Sedation algorithm in critically ill patients without acute brain injury. Crit Care Med. 2005;33(1):120–7.

43. Elliott R, McKinley S, Atkin LM, Hendrich J. The effect of an algorithm-based sedation guideline on the duration of mechanical ventilation in an Australian intensive care unit. Intensive Care Med. 2006;32(10):1506–14.

44. MacLaren R, Plamondon JM, Ramsay KB, Rocker GM, Patrick WD, Hall RI. A prospective evaluation of empiric versus protocol-based sedation and analgesia. Pharmacotherapy. 2000;20(6):662–72.

45. Mehta S, Bunn L, Cook D, Ferguson D, Steinberg M, Granton J, et al. Daily sedation interruption in mechanically ventilated critically ill patients cared for with a sedation protocol: a randomized controlled trial. JAMA. 2012;308(19):1985–92.

46. Minhas MA, Velasquez AG, Kaul A, Salinas PD, Celi LA. Effect of protocolized sedation on clinical outcomes in mechanically ventilated intensive care unit patients: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(5):613–23.

47. Paterson DP, Ladoire S, Devoucoux F, Doise JM, Cailliod R, Cunin N. Effect of a nurse-implemented sedation protocol on the incidence of ventilator-associated pneumonia [see comment]. Crit Care Med. 2007;35(9):2031–6.

48. Robinson BR, Mueller EW, Henson K, Branson RD, Barsoum S, Tieu BJ. An analgesia-delirium-sedation protocol for critically ill trauma patients reduces ventilator days and hospital length of stay. J Trauma. 2008;65(3):517–26.

49. Szklo B, Aher M, Leblanc M, Marquis F, Awissi DK, Kavanagh BP. Protocolized intensive care unit management of analgesia, sedation, and delirium improves analgesia and subsyndromal delirium rates. Anesth Analg. 2010;111(2):451–63.